U.S. Department of Health and Human Services
Jeffrey Kopp
 

 Contact Info

 
Tel: 301-594-3403
Email: jeffreyk@mail.nih.gov
 

 Select Experience

 
  • Consulting NephrologistMark Hatfield Clinical Research Center, NIHPresent
  • Commissioned Officer (Captain) Active Member (Rapid Deployment Force Teams PHS 1)U.S. Public Health ServicePresent
  • Adjunct Professor of MedicineUniformed Services University of the Health SciencesPresent
  • Senior InvestigatorNIDDK, NIH1995-present
  • Medical Staff FellowNIH1987-1995
  • Complete Training in Internal Medicine and NephrologyUniversity of Washington1987
  • M.D.University of Pennsylvania Medical School1980
  • B.A.Harvard College1975
 

 Related Links

 
Specialties
  • Clinical Research
  • Genetics/Genomics
  • Health Disparities

Research Summary

Current Research

Dr. Kopp leads a translational research group within the Kidney Disease Section, Kidney Diseases Branch, studying focal segmental glomerulosclerosis (FSGS) and related podocyte diseases.

Recent highlights

  • Chromosome 22 harbors a major risk locus for kidney disease in African Americans, including FSGS, HIV-associated nephropathy, and arterionephroclerosis (hypertension-attributed kidney disease).  APOL1 coding variants, which protect against trypanosomal infection, are strongly associated with kidney disease (odds ratios 7-29).  The mechanism of glomerular injury is unknown.
  • The HIV-1 protein Vpr, expressed in the glomerular podocytes, is sufficient to reproduce the chief features of HIV-associated collapsing glomerulopathy in transgenic mice.

Current research efforts

  • determining the mechanisms by which Apol1 variants damage the glomerulus
  • examining whether cardiotrophin-like cytokine 1 is a permeability factor that contributes to recurrent FSGS following kidney transplant
  • an open label phase II trial examining the efficacy of rituximab combined with cyclosporine (for 48 weeks) for treatment of refractory podocyte disease
  • participating in the ORD-funded NEPTUNE study of nephrotic diseases

Information for patients

  • We are actively recruiting individuals with focal segmental glomerulosclerosis and those with undiagnosed nephrotic syndrome or proteinuria.
  • All NIH trials are listed at clinicaltrials.gov.
  • Information about glomerular diseases is available on the Clomerular Disease Primer page​.

Reagents available to the research community

Transgenic mice

  • Podocin promoter/rTTA (reverse tetracycline transactivator)—also available from JAX and as herozygotes or homozygotes
  • TRE (tet responsive element)/Vpr
  • Alb/TGF-beta mice (request permission from Dr. Snorri Thorgeirsson, NCI)
  • Antibodies
  • rabbit polyclonal antibody to Vpr1-50 peptide—also available from AIDS Research and Reference Reagent Program
  • rabbit antiserum to human podocin (cross-reactive with mouse podocin)
  • rabbit antiserum to human nephrin (no cross-reactivity with mouse nephrin)
  • goat antimouse mesangial cell serum, for induction of glomerulonephritis in mice

Podocyte cell lines

  • mouse podocytes, immortalized with thermosensitive SV40 T Ag and bearing podocin/rtTA, for expression of genes of interest in cultured mouse podocytes
  • same, plus TRE silencer to reduce background expression
  • human urine derived podocyte-like epithelial cells (HUPECs), immortalized with hTERT and thermosensitive SV40 T Ag

Please contact us for further details.  NIDDK MTAs are available through Technology Advancement and Transfer.​